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Abstract. 
 
Peroxisomes are components of virtually all 
eukaryotic cells. While much is known about peroxiso-
mal matrix protein import, our understanding of how 
peroxisomal membrane proteins (PMPs) are targeted 
and inserted into the peroxisome membrane is ex-
tremely limited. Here, we show that PEX19 binds a 
broad spectrum of PMPs, displays saturable PMP bind-
ing, and interacts with regions of PMPs required for 
their targeting to peroxisomes. Furthermore, mislocal-
ization of PEX19 to the nucleus leads to nuclear accu-
mulation of newly synthesized PMPs. At steady state, 
PEX19 is bimodally distributed between the cytoplasm 
and peroxisome, with most of the protein in the cyto-
plasm. We propose that PEX19 may bind newly synthe-
sized PMPs and facilitate their insertion into the perox-
isome membrane. This hypothesis is supported by the 
observation that the loss of PEX19 results in degrada-
tion of PMPs and/or mislocalization of PMPs to the mi-
tochondrion.
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Introduction
 
The elaborate architecture of eukaryotic cells allows for
the concentration of integrated biochemical functions, the
segregation of competing metabolic processes, and the
creation of unique chemical environments. How the cell
assembles and maintains this complex array of subcellular
organelles is a central issue in cell biology. It is also a criti-
cal subject of evolutionary biology given that the genesis
of each organelle represents a watershed event in the evo-
lution of eukaryotic life. The peroxisome is a ubiquitous
organelle of eukaryotic cells that participates in a wide va-
riety of metabolic processes (Wanders and Tager, 1998).
However, the mechanism of peroxisome biogenesis has
yet to be elucidated, and there is no cogent model for the
genesis of this organelle.
The formation of peroxisomes must involve the genera-
tion of the peroxisome membrane, the targeting and inser-
tion of peroxisomal membrane proteins (PMPs)
 
1
 
 into this
membrane, and the transport of peroxisomal matrix pro-
teins to and across this same bilayer. Of these processes,
most is known about peroxisomal matrix protein import.
Proteins destined for the peroxisome matrix are encoded
by nuclear genes, synthesized in the cytoplasm (Lazarow
and Fujiki, 1985), and contain either of two peroxisomal
targeting signals, PTS1 and PTS2 (Subramani, 1993). Im-
port of these proteins is dependent upon PEX5 and PEX7,
the receptors for the PTS1 and PTS2 (McCollum et al.,
1993; Marzioch et al., 1994), and occurs in an ATP-depen-
dent manner (Imanaka et al., 1987). The fact that the PTS
receptors are predominantly cytoplasmic proteins (Marzi-
och et al., 1994; Dodt et al., 1995) has suggested models of
import in which the receptors act as shuttles, delivering
newly synthesized matrix proteins to the peroxisome
(Braverman et al., 1995; Dodt and Gould, 1996; Hettema
et al., 1999). These models also invoke a variety of other
peroxins that catalyze the translocation of proteins across
the peroxisome membrane and return the PTS receptors
to the cytoplasm.
Although peroxisomes play critical roles in numerous
metabolic pathways they are not essential for cell viability.
Therefore, it is not surprising that defects in peroxisome
biogenesis can cause human diseases by interfering with
peroxisomal metabolic processes. Zellweger syndrome
(ZS) and related diseases are characterized by defects in
peroxisome biogenesis and the loss of multiple peroxiso-
mal metabolic processes (Lazarow and Moser, 1995). Con-
sistent with the complexity of organelle biogenesis, muta-
tions in any of at least 12 different 
 
PEX
 
 genes can cause
ZS. In most cases, loss of 
 
PEX
 
 gene activity disrupts per-
oxisomal matrix protein import, but has no effect on the
synthesis of peroxisome membranes or import of peroxi-
somal membrane proteins (PMPs; Santos et al., 1988;
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Chang et al., 1999b). However, there are a few rare ZS pa-
tients who lack detectable peroxisomal structures, indicat-
ing that the genes defective in these patients, 
 
PEX3
 
,
 
PEX16
 
,
 
 
 
and 
 
PEX19
 
, are involved in synthesis of the per-
oxisome membrane or import of PMPs (Matsuzono et
al., 1999; South and Gould, 1999; South, S.T., K.A. Sack-
steder, S.J. Gould, manuscript in preparation). Studies in
yeast have identified up to 20 
 
PEX
 
 genes that are required
for peroxisome biogenesis, and again, most mutants ap-
pear competent for PMP import (Hettema et al., 1999).
PMPs are synthesized on free polyribosomes and post-
translationally inserted into the peroxisome membrane
(Fujiki et al., 1984; Imanaka et al., 1996). However, the
similarities between PMP import and peroxisomal matrix
protein import appear to end there. PMPs lack recogniz-
able PTS1- or PTS2-like features (Subramani, 1993), most
 
pex
 
 mutants that disrupt matrix protein import have no ef-
fect on PMP import (Chang et al., 1999b), and PMP im-
port appears to be ATP-independent (Diestelkotter and
Just, 1993). To better understand the molecular mecha-
nisms of PMP import and the synthesis of the peroxisome
membrane, we examined the biochemical properties of
PEX19, a protein that is required for the synthesis of per-
oxisome membranes in both human and yeast cells (Gotte
et al., 1998; Matsuzono et al., 1999). We report here that
human PEX19 is a predominantly cytoplasmic PMP-bind-
ing protein, and we discuss the relevance of our findings
for PMP import and peroxisome biogenesis.
 
Materials and Methods
 
Plasmids
 
The human 
 
PEX19
 
 open reading frame (ORF) was amplified from total
human cDNA and inserted into pcDNA3 (Invitrogen Corp.) to create
pcDNA3-
 
PEX19
 
. The plasmid pcDNA3-
 
PEX19
 
/C296A was created in
the identical manner except that the 3
 
9
 
 oligonucleotide encoded the
C296A mutation. The WT 
 
PEX19
 
 ORF was also cloned into the following
vectors: pPC86/LEU2, a dihybrid GAL4 activation domain (AD) fusion
vector, creating pPC86/LEU2-
 
PEX19
 
; pMBP, a modified form of the
pMALc2 expression vector (New England Biolabs Inc.); and pT7-6xHis, a
modified form of pET28A (Novagen, Inc.). pcDNA3-NLS/
 
PEX19
 
 was
constructed by appending a DNA fragment encoding the sequence MDK-
AEFLEAPKKKRKVEDPRNSSSVPGDPL upstream of the 
 
PEX19
 
ORF in pcDNA3 (NLS underlined). 
We have previously described the plasmids pcDNA3-
 
PEX10
 
, pcDNA3-
 
PEX10
 
myc (Warren et al., 1998), pcDNA3-
 
PEX11
 
b
 
, pcDNA3-
 
PEX11
 
b
 
myc
(Schrader et al., 1998), pcDNA3-
 
PEX12
 
, pcDNA3-
 
PEX12
 
myc (Chang et
al., 1997), pcDNA3-
 
PEX13
 
 (Bjorkman et al., 1998), and pcDNA3-
 
PECI
 
(Geisbrecht et al., 1999). The plasmids pcDNA3-
 
PEX3
 
, pcDNA3-
 
PEX14
 
,
pcDNA3-
 
PMP34
 
, pcDNA1/Amp-
 
PMP70
 
, pcDNA3-
 
ALDP
 
, and pcDNA3-
 
ALDR
 
 all contained the full-length ORF for the gene downstream of the
cytomegalovirus promoter and T7 promoter in the appropriate vector.
Myc tags were appended to these genes and to human 
 
PMP22
 
, 
 
PMP24
 
,
 
PEX11
 
a
 
, and 
 
PEX13
 
 by amplification using primers designed to append
Asp718 and BamHI sites at the 5
 
9
 
 and 3
 
9
 
 ends, respectively, and these
fragments were cloned upstream of and in-frame with a 12–amino acid
myc tag in the plasmid pcDNA3myc (Yahraus et al., 1996). The plasmids
pJL59W-
 
PEX10
 
, pJL59W-
 
PEX11
 
b
 
, pJL59W-
 
PEX12
 
, and pJL59W-
 
PEX13
 
contain the ORF of each gene in-frame with the GAL4 DNA binding do-
main of pJL59W. Control plasmids used in the blot overlay experiments
(SP6-
 
Tim23
 
, SP6-
 
Aac2
 
, SP6-
 
MIR1
 
, T7-
 
IBV-M
 
, and T7-
 
VSV-G
 
) were ob-
tained from Drs. Robert Jensen and Carolyn Machamer (The Johns Hop-
kins University School of Medicine, Baltimore, MD). The plasmids
pcDNA3-
 
PMP70
 
myc, pcDNA3-
 
D
 
C395
 
PMP70
 
myc, pcDNA3-
 
D
 
C476-
 
PMP70
 
myc, pcDNA3-
 
D
 
C535
 
PMP70
 
myc, pcDNA3-
 
D
 
C558
 
PMP70
 
myc,
pcDNA3-
 
D
 
C578
 
PMP70
 
myc, and pcDNA3-
 
D
 
C598
 
PMP70
 
myc were cre-
ated by amplifying the appropriate regions of the human PMP70 cDNA
 
with oligonucleotides designed to append an Asp718 site immediately up-
stream of the start codon (GGTACCATG; start codon underlined) and a
BamHI site after the last codon of the desired ORF. These fragments
were cleaved with Asp718 and BamHI and inserted between the Asp718
and BamHI sites of pcDNA3myc. The plasmids pcDNA3-
 
D
 
N119-
 
PEX11
 
b
 
myc, pcDNA3-
 
D
 
N180
 
PEX11
 
b
 
myc, pcDNA3-
 
D
 
N210
 
PEX11-
 
b
 
myc, pcDNA3-
 
D
 
C231
 
PEX14
 
myc, and pcDNA3-
 
D
 
C270
 
PEX14
 
myc were
all created in a similar fashion. Bacterial vectors designed to express
6xHis-PEX14, mutant forms of 6xHis-PEX14, 6xHis-PTE1, and 6xHis-
XECI were created by transferring the coding regions of each clone into
the bacterial expression vector, pT7-His (Geisbrecht et al., 1999). For all
plasmids, any regions generated by PCR were sequenced to ensure the ab-
sence of any unintended mutations.
 
Dihybrid Analysis and Blot Overlay Assays
 
The yeast strain BY3168 (Vidal et al., 1996) was used for all dihybrid as-
says. Pairs of plasmids, one encoding the appropriate binding domain
(BD) fusion, the other encoding the appropriate AD fusion, were used to
transform the yeast to leucine and tryptophan prototrophy. After selec-
tion, the modified strains were incubated at 30
 
8
 
C for 2 d, transferred to
BA-85 membranes (Schleicher and Schuell), grown for an additional 2 d,
and assayed for 
 
b
 
-galactosidase activity.
For blot overlay assays, all in vitro transcription/translation reactions
were performed using TNT rabbit reticulocyte lysates (Promega). 5 
 
m
 
g of
6xHis-PEX19 and a nonspecific control protein (XECI, a nuclear enoyl-
CoA isomerase) were resolved by SDS-PAGE electrophoresis and trans-
ferred to PVDF membrane. The membrane was blocked for 2 h at room
temperature in buffer A (500 mM Tris-HCl, pH 7.5, 50 mM NaCl, 100 mM
sodium acetate, 100 mM KCl, 1 mM DTT, 5 mM MgCl
 
2
 
, 1 mM EDTA,
0.3% Tween 20, 0.1 mM ZnCl
 
2
 
, 5% milk, 0.1 M methionine). The mem-
brane was incubated for 2 h at room temperature with 5 ml of buffer A
containing 
 
35
 
S-labeled PMPs that had been synthesized in vitro, washed,
and exposed to film. For far Western analysis, membranes containing 5 
 
m
 
g
of each protein were blocked as before, incubated with 10 ml of buffer A
containing 2 
 
m
 
g of purified 6xHis-PEX14, washed, and probed with affin-
ity-purified anti–PEX14 antibodies.
For quantitative analysis of PEX19-PEX14 binding, 
 
35
 
S-labeled 6xHis-
PEX14 was synthesized in vitro, mixed with bacterially expressed 6xHis-
PEX14, and the resulting mixture was applied at various concentrations to
membranes containing 100 ng of immobilized PEX19. After the binding
reaction, the filters were washed briefly and the amount of PEX14 bound
to PEX19 was determined using a PhosphorImager (MacBAS; Fuji). For
competition assays, a small amount of labeled PEX14 or PEX3 (
 
z
 
1–10 nM)
was mixed with the indicated concentrations of purified recombinant
PEX14, PTE1, or mutant forms of PEX14 and incubated with immobi-
lized PEX19 using the blot overlay technique. The labeled PMP bound
was detected using a PhosphorImager. All 6xHis-tagged proteins were
expressed and purified from bacteria as described (Geisbrecht et al.,
1999).
 
Transfections, Immunofluorescence, and
Antibody Production
 
Cell lines were cultured and transfected by electroporation and processed
for indirect immunofluorescence 4 h after transfection as described
(Chang et al., 1997, 1999b). Affinity-purified PEX19 antibodies were used
for all immunofluorescence experiments. Monoclonal mouse anti-myc an-
tibodies were obtained from the tissue culture supernatant of the hy-
bridoma 1-9E10 (Evan et al., 1985), guinea pig anti–PMP70 antibodies were
raised against the COOH-terminal 18 amino acids of human PMP70, and
secondary antibodies were obtained from commercial sources. Antibodies
directed against PEX19 were generated by immunization of rabbits with
an MBP-PEX19 fusion protein and were affinity-purified against immobi-
lized 6xHis-PEX19. The human skin fibroblast cell line GM5756-T was
used for the expression of proteins in normal human fibroblasts. The cell
line PBD399, which corresponds to the same Zellweger syndrome patient
cell line examined by Matsuzono et al. (1999), was used for the functional
complementation studies and for assessing PMP fates in the absence of
PEX19. The functional complementation studies were performed by
transfecting PBD399 cells by electroporation as described (Chang et al.,
1997) with the plasmids pcDNA3, pcDNA3-
 
PEX19
 
, and pcDNA3-
 
PEX19
 
/C296A. 3 d after transfection, the cells were processed for indirect
immunofluorescence using established protocols (Dodt and Gould, 1996)
and antibodies specific for catalase, which is a peroxisomal matrix protein. 
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Relative rescue activity was calculated as described (Chang and Gould,
1998).
 
Rat Liver Fractionation, Differential Centrifugation, 
Differential Permeabilization, and Immunoblotting
 
Preparation of rat liver postnuclear supernatant, separation of the periph-
eral nervous system by Nycodenz centrifugation and assay of marker en-
zymes were performed as described previously using a 15–45% Nycodenz
gradient (Mihalik, 1992). For differential centrifugation analysis, a rat
liver was homogenized, a postnuclear supernatant was generated, and
then spun at 25,000 
 
g 
 
for 30 min. This supernatant was removed and sub-
jected to further centrifugation at 200,000 
 
g 
 
for 1 h. Equal proportions of
the resulting homogenate, supernatants, and pellets were processed for
immunoblot with anti–PEX19 antibodies. For the differential release as-
say, GM5756-T fibroblasts were harvested by trypsinization, washed, and
divided into seven equal fractions. The cells were gently resuspended in
100 
 
m
 
l of STE (10 mM Tris, 1 mM EDTA, 250 mM sucrose) that was ad-
justed to various concentrations of digitonin (0, 50, 100, 200, 300, and 400
 
m
 
g/ml) or 400 
 
m
 
g/ml digitonin and 1% Triton X-100. After a 10-min incu-
bation on ice, clarified supernatants were generated by centrifugation and
analyzed by immunoblot. All immunoblots were performed using HRP-
conjugated secondary antibodies and chemiluminescent detection (Amer-
sham).
 
Results
 
PEX19 Binds Multiple Integral PMPs
 
One approach to understanding PEX19 function is to
identify those proteins with which it interacts. We used the
yeast two-hybrid assay as a crude screen to identify candi-
date PEX19-binding proteins. Full-length human PEX19
was expressed as a GAL4 AD fusion and screened against
a panel of GAL4 DNA BD fusions to all 14 known human
 
PEX
 
 proteins. Coexpression of AD-PEX19 and BD fu-
sions with PEX10, PEX11
 
b
 
, PEX12, or PEX13 led to acti-
vation of GAL4-regulated reporter genes, shown here by
LacZ filter assays (Fig. 1 A). These results were particu-
larly intriguing because PEX10, PEX11
 
b
 
, PEX12, and
PEX13 are all integral PMPs, but their roles in peroxisome
biogenesis differ: PEX11
 
b
 
 participates in the regulation of
peroxisome abundance (Schrader et al., 1998); PEX13 is
thought to act in matrix protein import as part of the re-
ceptor docking apparatus (Hettema et al., 1999); and
PEX10 and PEX12 act in matrix protein import down-
stream of receptor docking (Chang et al., 1999a). Al-
though we failed to detect an interaction signal in strains
that express AD-PEX19 and BD fusions with five other
peroxin PMPs (PEX2, PEX3, PEX11
 
a
 
, PEX14, and
PEX16), negative results in this assay can be caused by a
variety of nonspecific problems, such as poor expression,
improper folding, and failure to target to the nucleus, none
of which were controlled for in this study. Furthermore, it
should be noted that the yeast two-hybrid assay is gener-
ally not useful for assessing interactions with integral
membrane proteins (Drees, 1999) such as the PMPs tested
here.
The interaction of PEX19 with a diverse array of PMPs
in the yeast two-hybrid assay raised the possibility that
PEX19 might be a general PMP-binding protein, perhaps
with a role in PMP biogenesis. However, an analysis of
PEX19–PMP interactions in a biochemical assay system
would be necessary to test this hypothesis. To this end, we
expressed and purified recombinant PEX19 in bacteria
and tested whether it could bind a variety of integral PMPs
with diverse functions. Equal amounts of recombinant
PEX19 and a nonspecific control protein (XECI; Geis-
brecht, B.V., and S.J. Gould, unpublished observations) were
separated by SDS-PAGE, transferred to membranes, and
Figure 1. PEX19 displays specific PMP-binding activity. (A)
Yeast strains expressing the GAL4 transcription activating do-
main (AD) or an AD-PEX19 fusion with the GAL4 DNA bind-
ing domain (BD) and BD-PEX10, BD-PEX11b, BD-PEX12, and
BD-PEX13 were grown on filters, lysed, and assayed for LacZ
activity using the indicator substrate X-gal. (B) Purified recombi-
nant 6xHis-PEX19 (left lanes) and 6xHis-XECI (right lanes)
were resolved by SDS-PAGE and either stained with Coomassie
blue (top left panel) or transferred to PVDF membranes and
probed with 35S-labeled, in vitro translated PEX12, PEX13,
PEX3, PEX14, PMP70, PMP34, PECI, PEX19, VSV-G, IBV-M,
Tim23, Aac2, or Mir1. After washes, the filters were exposed to
film. The bottom right panel shows a far Western blot in which a
similar filter was incubated with purified recombinant PEX14,
washed, probed with affinity-purified anti–PEX14 antibodies,
and detected using HRP-conjugated secondary antibodies and
chemiluminescent detection. 
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renatured. Replicate filters were probed with seven differ-
ent 
 
35
 
S-labeled human integral PMPs at concentrations
ranging from 1 to 10 nM. Recombinant PEX19 bound
PEX12 and PEX13, two of the PMPs that interacted with
PEX19 in the yeast two-hybrid assay, as well as to two
other peroxin PMPs, PEX3 (Kammerer et al., 1998) and
PEX14 (Fransen et al., 1998; Fig. 1 B). Importantly,
PEX19 also bound three PMPs that do not appear to par-
ticipate in peroxisome biogenesis: PMP70, a peroxisomal
ATP-binding cassette transporter (Kamijo et al., 1990);
PMP34, a peroxisomal solute carrier (Wylin et al., 1999;
Fig. 1 B); and ALDR (data not shown), another ATP-
binding cassette transporter of the peroxisome membrane
(Lombard-Platet et al., 1996).
We also examined the specificity of PEX19 for integral
PMPs (Fig. 1 B). We found that PEX19 does not bind per-
oxisomal matrix proteins, shown here by its inability to
bind peroxisomal enoyl-CoA isomerase (PECI; Geisbrecht
et al., 1999), nor does it bind to itself. PEX19 was also un-
able to bind to integral membrane proteins of other or-
ganelles, including an integral plasma membrane protein
(VSV-G; Adams and Rose, 1985), an integral Golgi mem-
brane protein (IBV-M; Boursnell et al., 1984), and three in-
tegral mitochondrial membrane proteins (Tim23; Dekker
et al., 1993), Aac2 (Lawson and Douglas, 1988), and Mir1
(Murakami et al., 1990). It should be noted that these con-
trol membrane proteins were added at approximately the
same concentration as the PMPs that did bind to PEX19.
To test whether PEX19-PMP binding was direct, we ex-
pressed and purified a small amount of soluble PEX14
from bacteria (it was the only PMP that we were able to
purify in soluble form). We performed the blot overlay as-
say using recombinant PEX14 rather than in vitro trans-
lated PEX14. The ability of PEX19 to bind recombinant
PEX14 was determined by blotting with affinity-purified
anti–PEX14 antibodies. This far Western assay revealed
that recombinant PEX19 was indeed able to bind purified
PEX14 in the absence of any other factors (Fig. 1 B).
The blot overlay assay was also used to examine the
thermodynamic parameters of PEX19-PMP binding. Im-
mobilized PEX19 was incubated with various concentra-
tions of recombinant PEX14 spiked with 
 
35
 
S-labeled PEX14,
and the relative amounts bound were quantitated using a
PhosphorImager (Fig. 2 A). Binding was saturated at con-
centrations of 3 
 
m
 
M and above in three independent ex-
periments. The actual dissociation constants
 
 
 
calculated in
the three trials were 350, 800, and 500 nM, suggesting a
PEX14-PEX19 dissociation constant of 
 
z
 
500 nM. To as-
sess the specificity of PEX19 binding, we tested the ability
of peroxisomal thioesterase (PTE1; Jones et al., 1999), a
peroxisomal matrix protein, and PEX14 to compete 
 
35
 
S-
labeled PMPs from binding to PEX19 (Fig. 2 B). Excess
unlabeled PEX14 effectively competed labeled PEX14
from PEX19, but excess PTE1 had no effect on PEX19-
PEX14 binding. Specific competition was also observed
when PTE1 and PEX14 were assayed for their ability to
compete with labeled PEX3 for PEX19 binding.
 
Mislocalization of PEX19 Results in Mislocalization of 
Newly Synthesized PMPs
 
The specific binding of PEX19 to seven PMPs with diverse
functions in metabolite transport (PMP70, PMP34, and
ALDR), peroxisomal matrix protein import (PEX10,
PEX12, and PEX14), and peroxisome membrane biogene-
sis (PEX3) strongly suggests that PEX19 is a broad speci-
ficity PMP-binding protein. We tested this hypothesis, as
well as whether PEX19 could bind PMPs within human
cells, using a completely independent assay. Specifically,
we targeted PEX19 to the nucleus and asked whether this
resulted in nuclear accumulation of newly synthesized
PMPs. Wild-type PEX19 accumulates in the cytoplasm
when overexpressed (Fig. 3 A), but a form of PEX19 con-
taining a nuclear localization signal (NLS/PEX19) is in-
stead targeted to the nucleus (Fig. 3, B and C). Normal hu-
man fibroblasts were cotransfected with plasmids designed
to express a variety of epitope-tagged PMPs and either
pcDNA3 or pcDNA3-NLS/
 
PEX19
 
. 4 h after transfection,
the distribution of the newly synthesized PMPs was deter-
mined by immunofluorescence microscopy. As expected
for a PMP, PEX14myc was imported into peroxisomes in
cells cotransfected with pcDNA3. In contrast, PEX14myc
was found in the nucleus of cells that were cotransfected
with pcDNA3-NLS/
 
PEX19
 
 (Fig. 3, D–F). This PMP was
never detected in the nucleus in the absence of NLS/
PEX19 expression. NLS/PEX19 expression also resulted
in the nuclear import of newly synthesized PMP34myc,
ALDPmyc (a myc-tagged version of another nonperoxin
PMP [Mosser et al., 1993, 1994]), PEX3myc, PEX11
 
b
 
myc,
and PEX12myc (Chang et al., 1997; Fig. 3, G–U). Simi-
lar  results were observed for PMP70myc, ALDRmyc,
PEX10myc (Warren et al., 1998), PEX11
 
a
 
myc (Schrader
Figure 2. PEX19-PMP binding is saturable. (A) Purified 6xHis-
PEX19 was separated by SDS-PAGE, transferred to PVDF
membranes, and incubated with purified recombinant 6xHis-
PEX14 spiked with 35S-labeled 6xHis-PEX14 at various concen-
trations, washed, and analyzed using a PhosphorImager. The
amount of PEX14 bound at each concentration was determined
and plotted versus 6xHis-PEX14 concentration using Kaleida-
Graph software. (B) Membranes containing 1 mg of immobilized
6xHis-PEX19 were incubated with 35S-PEX14 (left) or 35S-PEX3
(right) in buffer A (left lanes), buffer A containing 10 mM 6xHis-
PTE1 (middle lanes), and buffer A containing 10 mM 6xHis-
PEX14 (right lanes). 
Sacksteder et al. 
 
PEX19 Is a PMP-binding Protein
 
935
 
et al., 1998), PEX13myc, PEX16myc (South and Gould,
1999), PMP24myc (Reguenga et al., 1999), and PMP22myc
(Diestelkotter and Just, 1993; data not shown).
To control for the specificity of this nuclear mislocaliza-
tion assay we also examined the effects of NLS/PEX19
on the distribution of PTE1, a peroxisomal thioesterase
(Jones et al., 1999). PTE1 was imported into peroxisomes
regardless of NLS/PEX19 expression (Fig. 3, V–X). Simi-
lar results were observed for PECI, another peroxisomal
matrix protein (data not shown). Furthermore, NLS/
PEX19 did not affect the distribution of PMPs that al-
ready had been imported into peroxisomes, shown here
by the presence of endogenously expressed PMP70 in
vesicles with the typical morphology of peroxisomes in
cells expressing NLS/PEX19 (Fig. 3, Y–AA). All together,
the nuclear mislocalization assay provided evidence that
PEX19 interacts with 14 PMPs of diverse functions in
peroxisome biogenesis and metabolite transport, confirm-
ing all seven examples of PEX19-PMP binding obtained
in the blot overlay experiments and all four examples
of PEX19-PMP binding detected in the yeast two-hybrid
assay.
Figure 3. Targeting PEX19 to the nucleus leads
to nuclear accumulation of PMPs. (A–C) Human
fibroblasts expressing PEX19 (A) or NLS/PEX19
(B and C) were analyzed by indirect immunoflu-
orescence using affinity-purified anti–PEX19 an-
tibodies (A and B) and stained with DAPI (C).
Human fibroblasts expressing the myc-tagged
PMPs PEX14 (D–F), PMP34 (G–I), ALDP
(J–L), PEX3 (M–O), PEX11b (P–R), or PEX12
(S–U), or the peroxisomal matrix protein PTE1
(V–X) with pcDNA3 alone (left column) or with
pcDNA3-NLS/PEX19 (middle and right col-
umns) were analyzed by indirect immunofluores-
cence using monoclonal anti–myc antibodies
with appropriate secondary antibodies (left and
middle columns) and DAPI (right column). Fi-
broblasts transfected with pcDNA3 (Y) or
pcDNA3-NLS/PEX19 (Z and AA) were ana-
lyzed by indirect immunofluorescence using anti–
PMP70 antibodies (Y and Z) with appropriate
secondary antibodies. Cells expressing NLS/
PEX19 were also stained with DAPI (AA). Bar,
15 mm. 
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Targeting Elements of PMPs Retain Interaction
with PEX19
 
The ability of PEX19 to bind PMPs of diverse function im-
plicates PEX19 in the biogenesis of PMPs. One obvious
possibility is that PEX19 may interact with regions of
PMPs that are involved in targeting to peroxisomes. To
test whether this might be true, we examined the regions
of several human PMPs that are required for targeting to
peroxisomes and tested whether they retained the ability
to bind to PEX19. The integral PMPs, PMP70, PEX11
 
b,
and PEX14, were chosen for these studies. COOH-termi-
nal truncations of PMP70, each of which carried a COOH-
terminal myc epitope tag, were expressed in human fibro-
blasts and their subcellular distributions were determined
by immunofluorescence. The first 124 amino acids of
PMP70 were sufficient to direct it into peroxisomes (Fig. 4,
B and C). This same segment of PMP70 is efficiently mis-
directed to the nucleus in cells that overexpress NLS/
PEX19 (Fig. 4, D and E). The first 101, 81, or 61 amino ac-
ids of PMP70 are also able to mediate peroxisomal target-
ing but only at reduced efficiency. These shorter pieces of
PMP70 were localized to both peroxisomes and mitochon-
dria, as shown here for DC598 PMP70, the smallest of the
three proteins (Fig. 4, F and G). The positive identification
of the tubulovesicular structures as mitochondria was con-
firmed by colocalization with a mitochondrial marker (Mi-
Figure 4. PEX19 binds the peroxisomal targeting
element of PMP70. (A) Line diagram of PMP70
mutants. Full-length PMP70 is shown at the top,
and predicted transmembrane domains are
shown in black boxes. Subcellular distribution
and interaction with PEX19 are indicated to the
right. Normal human fibroblasts expressing the
PMP70 mutant constructs DC535PMP70myc
(B–E) or DC598PMP70myc (F–I) were cotrans-
fected with either vector alone (B, C, F, and G)
or pcDNA3-NLS/PEX19 (D, E, H, and I). The
distribution of the PMP70 truncation mutants
was determined by immunofluorescence using
anti–myc antibodies (left). Cells cotransfected
with vector alone were stained with antibodies to
the COOH terminus of PMP70 (C and G),
whereas cells cotransfected with pcDNA3-NLS/
PEX19 were stained with DAPI (E and I). Bar,
15 mM.Sacksteder et al. PEX19 Is a PMP-binding Protein 937
toTracker; data not shown). These three pieces of PMP70
retained their ability to interact with PEX19, as seen by
the misdirection of DC598 PMP70 to the nucleus in cells
overexpressing NLS-PEX19 (Fig. 4, H and I).
Similar results were observed for PEX11b. Targeting
studies revealed that the COOH-terminal 78 amino acids
of this 259–amino acid-long protein were sufficient for
both peroxisomal localization and interaction with PEX19
(Fig. 5, A–E). The COOH-terminal 49 amino acids of
PEX11b were also directed to the peroxisome, though at
reduced efficiency, and also retained the ability to interact
with PEX19 (Fig. 5, F–I).
These results are consistent with the hypothesis that
PEX19 may bind to PMP targeting elements. However,
they are qualitative in nature since they rely on the nuclear
mislocalization assay for assessing PEX19 interaction. To
apply a more quantitative PEX19 binding assay to this
question, we performed a limited analysis of PEX14 tar-
geting elements. Epitope-tagged forms of PEX14 were
generated and their subcellular distributions were deter-
mined by immunofluorescence. Full-length PEX14 was ef-
ficiently imported into peroxisomes, but a fragment of
PEX14, containing amino acids 1–108, did not associate
with peroxisomes (Fig. 6, A–E). A segment of PEX14,
containing amino acids 1–147, associated with peroxi-
somes but only poorly, with much of the protein being im-
ported into mitochondria (Fig. 6, F and G). The affinity of
PEX19 for these three forms of PEX14 was determined
by expressing and purifying each protein from bacteria
and assaying its ability to compete labeled PEX14 from
Figure 5. PEX19 binds the peroxisomal targeting
element of PEX11b. (A) Line diagram of PEX11
(truncations, their subcellular distribution, and
their ability to interact with PEX19 in the nuclear
localization assay). Solid boxes show the position
of the two transmembrane domains. (B–I) Sub-
cellular distribution of two truncated forms of
PEX11b in normal cells and in cells expressing
NLS/PEX19. Normal human fibroblasts were
transfected with pcDNA3-DN180/PEX11 (B-E)
or pcDNA3-DN210/PEX11b (F–I) and cotrans-
fected with a vector control (B, C, F, and G) or
pcDNA3-NLS/PEX19 (D, E, H, and I). Cells
were processed for indirect immunofluorescence
using antibodies specific for the myc epitope tag
(B, D, F, and H) and colabeled with antibodies
specific for endogenously expressed PMP70 (C
and G) or DAPI (E and I). Bar, 15 mm.The Journal of Cell Biology, Volume 148, 2000 938
PEX19. Unlabeled full-length PEX14 effectively displaced
labeled PEX14 at a concentration of 10 mM, as expected
(Fig. 6 H). The mutant containing amino acids 1–147 of
PEX14, which was targeted to peroxisomes only poorly,
also competed poorly: the 1–147-amino acid segment
showed weak competition at 10 mM, competed 50% of the
labeled PEX14 from PEX19 at a concentration of 30 mM,
and reduced the amount of labeled PEX14 to 10% of the
control at a concentration of 100 mM. The fragment of
PEX14 that was not transported to peroxisomes, amino
acids 1–108, failed to compete labeled PEX14 from PEX19
at all three concentrations. These results are consistent
with the hypothesis that PMP targeting elements retain
PEX19 binding. However, these results do not establish
that PEX19 binds to PMP targeting signals, for we have
yet to identify the targeting signals in these human PMPs.
PEX19 Is Bimodally Distributed between the Cytoplasm 
and Peroxisome
To better understand the biological basis of PEX19–PMP
interactions we assessed the distribution of PEX19 within
the cell. A rat liver postnuclear supernatant was separated
by Nycodenz density gradient centrifugation, assayed for
marker enzymes of peroxisomes, mitochondria, and cyto-
sol, and blotted with affinity-purified anti–PEX19 antibod-
ies. These experiments indicated that the majority of
PEX19 was present in the cytoplasm, but that detectable
levels were present in the peroxisomal fractions (Fig. 7 A).
The presence of PEX19 in purified peroxisomes was also
confirmed by blotting a sample of purified peroxisomes
(Fig. 7 B). We also performed differential centrifugation
experiments to determine whether any of the apparently
cytosolic PEX19 can be pelleted at high speed. A small
amount of PEX19 pellets at 25,000 g, as expected for a
peroxisome-associated protein, and the PEX19 present in
the 25,000-g supernatant cannot be pelleted even after
centrifugation at 100,000 g (Fig. 7 C).
To control for the possibility that PEX19 might have
been released from peroxisomes by homogenization, we
also assessed the distribution of PEX19 using a differential
permeabilization and release assay. Intact human fibro-
blasts were incubated with varying amounts of digitonin,
which preferentially permeabilizes the plasma membrane,
and the material released from the cells at each concentra-
tion was collected. These fractions were assayed for a cyto-
solic marker enzyme (LDH), PEX19, and a peroxisomal
marker protein (catalase). Most PEX19 was released at
concentrations that also released LDH from the cell, sup-
porting the hypothesis that significant amounts of PEX19
reside in the cytoplasm (Fig. 7 C). It should be noted that
20% of LDH activity and 30–40% of PEX19 were released
only after the addition of 1% Triton X-100.
PEX19 is a farnesylated protein and it is possible that
PEX19 might use its farnesyl group to associate with per-
Figure 6. Analysis of PEX14 targeting and interaction with
PEX19. (A) Line diagram of PEX14 truncation mutations. Solid
boxes show the position of the transmembrane domain. (B–G)
Normal human fibroblasts expressing PEX14myc (B and C),
DC231PEX14myc (D and E), or DC270PEX14myc (F and G) were
processed for indirect immunofluorescence using antibodies
specific for the myc epitope tag (left) and PMP70 (right) using
appropriate secondary antibodies. (H) Competition of PEX14-
PEX19 binding by WT and mutant PEX14 proteins. Purified
6xHis-PEX19 was separated by SDS-PAGE, transferred to PVDF
membranes, and probed with equal amounts of 35S-labeled
PEX14 in buffer A or buffer A containing various concentrations
of 6xHis-PEX14, 6xHis-DC231PEX14, and 6xHis-DC270PEX14.
Membranes were washed and the amount of 35S-labeled PEX14
bound to PEX19 was determined using a PhosphorImager. These
values were normalized to the control reaction and plotted on a
bar graph. Bar, 15 mM.Sacksteder et al. PEX19 Is a PMP-binding Protein 939
oxisome membranes. If true, the homogenization and
permeabilization experiments may have released PEX19
from peroxisomes without affecting the distribution of
other peroxisomal proteins. Because it is virtually im-
possible to control directly for this possibility, we decided
instead to address this issue indirectly by determining
whether farnesylation was critical for PEX19 function.
PEX19 is farnesylated via the cysteine residue at position
296, and we generated a PEX19 mutant in which this
cysteine is replaced by an alanine (PEX19/C296A) and is,
therefore, unable to accept the farnesyl moiety. We trans-
fected a PEX19-deficient human fibroblast cell line with
pcDNA3, pcDNA3-PEX19, and pcDNA3-PEX19/C296A,
and assessed the ability of each plasmid to restore peroxi-
some biogenesis in these cells (Fig. 7, D–F). Transfection
with the empty vector had no effect, expression of WT
PEX19 led to rescue of peroxisome biogenesis in z50%
of the cells, and expression of PEX19/C296A led to resto-
ration of peroxisome biogenesis in a similarly high num-
ber of the cells. Quantitation of relative rescue activities
revealed that the C296A mutation had only a mild effect
on PEX19 activity, reducing it to z80% the activity of
wild-type PEX19. Therefore, it appears that farnesylation
has an ancillary effect on PEX19 function and that
PEX19 functions well in the absence of the farnesyl
moiety.
PMP Fates in the Absence of PEX19
It has been established previously that PMP70 is present
at greatly reduced levels in PEX19-deficient mammalian
cells, and that this is caused by an increased rate of PMP70
degradation (Kinoshita et al., 1998; Matsuzono et al.,
1999). We examined the fates of additional PMPs in
PEX19-deficient cells to assess the role of PEX19 in the
biogenesis of other PMPs. Immunofluorescence studies
showed that normal human fibroblasts contain hundreds
of PMP70-containing peroxisomes but, as previously dem-
onstrated, PEX19-deficient cells lack detectable PMP70-
containing structures (Fig. 8, A and B). Similar results
were observed when these cells were stained with antibod-
ies specific for the integral PMPs PEX13 and PEX11b
(Fig. 8, C–F). However, not all PMPs were undetectable in
PEX19-deficient cells. Immunoblot experiments revealed
that the integral PMP PEX14 was present at similar levels
in PEX19-deficient cells as in other PEX mutants (data
not shown) and was easily detectable in these cells by im-
munofluorescence. However, the PEX14 in these cells was
not present in peroxisome-like structures or other small
vesicles, but was instead mislocalized to the mitochondria
(Fig. 9, A–C). Similar mitochondrial mislocalization was
observed for myc-tagged derivatives of several integral
PMPs that were introduced by transfection. These in-
cluded the integral PMPs PEX12 (Fig. 9, D–F) and ALDP
(Fig. 9, G–I). Similar mitochondrial mislocalization was
observed when PEX13 and PEX11b were overexpressed
in the PEX19-deficient cells (data not shown). Snyder et al.
(1999) recently reported that minute, PEX3-containing
minivesicles may exist in PEX19-deficient cells of the
yeast Pichia pastoris. We could not directly test whether
similar structures exist in human PEX19-deficient cells be-
cause we lack antibodies of sufficient titer to PEX3. How-
ever, myc-tagged PEX3, like the other PMPs we tested,
was easily detected in peroxisomes of normal cells, but was
mislocalized to mitochondria of PEX19-deficient cells
(Fig. 9, J–L).
Figure 7. Subcellular distribution of mammalian PEX19. (A) A
postnuclear supernatant of rat liver was fractionated by centrifu-
gation on a 15–45% Nycodenz gradient and the position of the
peroxisomal marker (catalase, solid line), the mitochondrial
marker (succinate dehydrogenase, dotted line), and a cytoplas-
mic marker (lactate dehydrogenase, dashed line) are shown. The
bottom of the gradient (most dense) is to the left, and the abun-
dance of PEX19 in each fraction was determined by immunoblot
(lower panel, arrow). (B) Highly purified rat liver peroxisomes
were separated by SDS-PAGE and PEX19 was detected by im-
munoblot (arrow). (C) Rat liver was homogenized and subjected
to differential centrifugation analysis. Equal proportions of ho-
mogenate, 25,000 g pellet, 25,000 g supernatant, 100,000 g pellet,
and 100,000 g supernatant fractions were separated by SDS-
PAGE and assayed by immunoblot for PEX19. (D) Human fi-
broblasts (GM5756-T) were harvested and incubated with vary-
ing amounts of digitonin, as well as digitonin and Triton X-100.
Insoluble material was pelleted by centrifugation, and the super-
natants were assayed for the release of cytoplasmic (LDH,
square) and peroxisomal (catalase, circle) markers and for
PEX19 by immunoblot (diamond). (E–G) Fibroblasts were
transfected with pcDNA3 (E), pcDNA3-PEX19 (F), or
pcDNA3-PEX19/C296A (G) and processed by immunofluores-
cence using antibodies to catalase and the appropriate secondary
antibodies.The Journal of Cell Biology, Volume 148, 2000 940
Discussion
The import of nuclear-encoded peroxisomal proteins is a
critical aspect of peroxisome biogenesis. Although much is
known about peroxisomal matrix protein import, less is
known about PMP import. PMPs, like peroxisomal matrix
proteins, are synthesized on cytoplasmic ribosomes and
imported posttranslationally, but it is unclear how the cell
recognizes PMPs, directs them to the peroxisome, and in-
serts them into the peroxisome membrane bilayer. PMPs
lack the PTS1 and PTS2 signals that direct proteins to the
peroxisome matrix and do not require either the PTS1 or
PTS2 receptors for import into peroxisome membranes
(Chang et al., 1999b). Mutants that are defective in PMP
import would be expected to lack detectable peroxisomal
structures, and this phenotype has been reported for a
Zellweger syndrome patient with mutations in PEX19, as
well as a Saccharomyces cerevisiae pex19 mutant (Gotte
et al., 1998; Matsuzono et al., 1999). In this report, we ob-
served that PEX19 is a predominantly cytoplasmic PMP-
binding protein that is required for the proper biogenesis
of numerous PMPs.
PEX19 Is a Broad Specificity PMP-binding Protein
Using a blot overlay assay, we found that PEX19 binds to
a broad spectrum of PMPs with diverse functions in perox-
isome biogenesis (PEX3, PEX12, PEX13, and PEX14)
and metabolite transport (PMP70, PMP34, and ALDR).
The binding activity of PEX19 appeared to be specific for
PMPs as PEX19 failed to bind peroxisomal matrix pro-
teins or integral membrane proteins that reside in the
plasma, Golgi, or mitochondrial membranes. The fact that
PEX19-PMP binding could be assayed in vitro allowed us
to further characterize the nature of PEX19-PMP binding.
Using PEX14 as a test PMP, we found that the PEX19–
PMP interaction displayed a dissociation constant of z500
nM, which is well within the range expected for a revers-
ible protein–protein interaction. For comparison, it is in-
teresting to note that the complex between PTS1-contain-
ing peroxisomal matrix proteins and PEX5, the PTS1
receptor, also has a dissociation constant of z500 nM
(Terlecky et al., 1995).
The interaction between PEX19 and these same seven
PMPs was also tested in an independent PEX19-binding
assay in which a nuclear localization signal was appended
to PEX19 and the resulting NLS/PEX19 protein was as-
sayed for its ability to mislocalize newly synthesized PMPs
to the nucleus. In this second assay, PEX19 interacted with
14 human PMPs, including the same set of 7 PMPs that
PEX19 bound to in the blot overlay assay (PEX3, PEX12,
PEX13, PEX14, PMP70, PMP34, and ALDR) as well as 7
more PMPs (PEX10, PEX11a, PEX11b, PEX16, ALDP,
Figure 8. A subset of PMPs is
not detectable in PEX19-defi-
cient cells. Wild-type (left col-
umn) and PBD399 (right col-
umn) human fibroblasts were
processed for indirect immuno-
fluorescence using antibodies
specific for PMP70 (A and B),
PEX13 (C and D), and PEX11b
(E and F) with the appropriate
secondary antibodies. Bar, 15 mm.Sacksteder et al. PEX19 Is a PMP-binding Protein 941
PMP22, and PMP24). Furthermore, we observed that
PEX19 interacted with four human PMPs in the yeast two-
hybrid assay: PEX10, PEX11b, PEX12, and PEX13. All
told, we observed interaction of PEX19 with nine human
PMPs in at least two independent assays (PEX12 and
PEX13 in all three assays; PEX3, PEX14, PMP70, PMP34,
ALDR in the blot overlay and nuclear mislocalization as-
says; and PEX11b and PEX10 in the two-hybrid and nu-
clear mislocalization assays) and 14 human PMPs alto-
gether. It should be noted that ours are not the first
evidence that PEX19 can bind PMPs, as previous reports
have demonstrated that S. cerevisiae PEX19 binds PEX3
(Gotte et al., 1998) and that P. pastoris PEX19 binds
PEX3 and PEX10 (Snyder et al., 1999). Although we
did not detect interaction of PEX19 with several PMPs
assayed in the yeast two-hybrid assay (PEX2, PEX3,
PEX11a, PEX14, and PEX16), these results are difficult to
interpret in the absence of controls for the expression,
folding, and nuclear targeting of the various GAL4BD-
PMP fusion proteins.
PMP Targeting Elements Retain the Ability to
Bind PEX19
The interaction of human PEX19 with a diverse array of
human PMPs, the ability of NLS/PEX19 to draw newly
synthesized, but not mature, PMPs into the nucleus, and
the inability of PEX19-deficient cells to import PMPs all
indicate that PEX19 plays an important role in PMP bio-
genesis, perhaps in the recognition of PMP targeting sig-
nals or as a chaperone for newly synthesized PMPs. If true,
we would expect that regions of PMPs that were sufficient
for targeting to peroxisomes would retain the ability to
bind PEX19, and we tested this for three integral PMPs,
PMP70, PEX11b, and PEX14.
We found that the first 61 amino acids of PMP70 (,10%
of the protein) are sufficient for peroxisomal localization
and that this same segment of PMP70 retained the ability
to interact with PEX19. The analysis of PEX11b provided
similar results, with the COOH-terminal 49 amino acids of
PEX11b being sufficient for both targeting and interaction
with PEX19. We also used a more quantitative method for
the analysis of PEX14-PEX19 binding. Targeting studies
revealed that the first 147 amino acids of PEX14 targeted
to peroxisomes, though weakly, and bound to PEX19 with
a much lower affinity than full-length PEX14. We also
found that the first 108 amino acids of PEX14 could not
bind to PEX19, and that this fragment of PEX14 could not
localize to peroxisomes. Taken together, these results are
consistent with the hypothesis that targeting elements of
PMPs retain the ability to bind PEX19.
It is important to note that the targeting elements de-
scribed in this paper cannot be equated with the minimal
targeting signals for these PMPs; thus, the question of
whether PEX19 binds to PMP targeting signals remains to
be addressed. However, our inability to identify the PMP
targeting signals in PMP70 and PEX11b was not due to a
lack of effort. For both PMP70 and PEX11b, we were un-
able to identify regions smaller than z50–60 amino acids
that could target to peroxisomes, and we have encoun-
Figure 9. A subset of PMPs
localizes to mitochondria in
PEX19-deficient cells. The dis-
tribution of endogenous PEX14
was determined in wild-type (A)
and PBD399 (B) fibroblasts us-
ing affinity-purified PEX-14 an-
tibodies. The distribution of
PEX12myc (D and E), ALDP-
myc (G and H), and PEX3myc (J
and K) was determined in wild-
type (D, G, and J) and PBD399
(E, H, and K) fibroblasts using
antibodies specific to the myc
epitope. PBD399 fibroblasts
were also stained with Mi-
toTracker (C, F, I, and L). The
peroxisomal nature of the punc-
tate structures in wild-type fibro-
blasts was confirmed by double
label with anti–PMP70 antibodies
(data not shown). Bar, 15 mm.The Journal of Cell Biology, Volume 148, 2000 942
tered similar problems during searches for targeting sig-
nals in the PMPs PMP34, PEX12, and PEX13 (data not
shown). Such problems were not encountered during the
search for targeting signals in peroxisomal matrix proteins
(Subramani, 1993), and this difference is worth discussing.
It is our opinion that the difficulty in identifying concise
PMP targeting signals lies in the nature of protein target-
ing assays. Conventional targeting assays obviously mea-
sure the targeting abilities of the test proteins, but it is gen-
erally not appreciated that they also measure the retention
of the protein in the organelle after the targeting event. In
the case of peroxisomal matrix proteins, the retention is
provided by the passive barrier of the peroxisome mem-
brane and the assay, therefore, reflects just the targeting
information of the protein. In contrast, it is difficult to en-
vision how PMPs could be retained unless they were in-
serted into the peroxisome membrane, a process that is
unlikely to be passive. Thus, biologically defined PMP tar-
geting signals are likely to include signals for two poten-
tially distinct processes: targeting, which may involve the
recognition by a PMP receptor, and retention, which may
require insertion of the protein into the peroxisome mem-
brane. The targeting elements we identified in PMP70,
PEX11b, and PEX14 all contained a putative transmem-
brane domain, and it will be interesting to determine the
nature of the PEX19-binding sites in these and other PMP
targeting elements.
In addition to the test proteins we used for determining
whether peroxisomal targeting elements retained the abil-
ity to bind to PEX19, it is necessary to discuss three pro-
teins that we did not use in these particular experiments.
The first is Candida boidinii PMP47. If we define a PMP
targeting signal as the minimal regions that are sufficient
for targeting to peroxisomes and for which the functional
elements are known, the only PMP targeting signal in the
literature that meets this criteria is the mPTS of C. boidinii
PMP47 (Dyer et al., 1996). We considered testing whether
PEX19 recognized this mPTS, but we found that this sig-
nal is not sufficient for peroxisomal membrane targeting in
human cells (Gould, S.J., unpublished observations) and it
was, therefore, unclear what benefit could come from such
an analysis. The other two proteins that deserve mention
are PEX3 and PEX16. We detected interactions between
PEX19 and these two PMPs. Like any other integral PMPs
we might have considered using PEX3 or PEX16 to test
whether PEX19-binding sites reside within their PMP tar-
geting elements. This is particularly true for PEX3 since
previous studies have localized a low efficiency PMP tar-
geting element to within the first 40 amino acids of this
PMP (Kammerer et al., 1998; Soukupova et al., 1999).
However, we consciously avoided using these PMPs for
these particular experiments because they, like PEX19,
are required for peroxisome membrane biogenesis along
with PEX19 (Hettema et al., 1999; Matsuzono et al., 1999;
South and Gould, 1999; South, S.T., K.A. Sacksteder, and
S.J. Gould, unpublished observations). Thus, they may in-
teract with PEX19 in multiple places and for multiple pur-
poses. For example, it is possible that PEX19 could inter-
act with targeting elements during the biogenesis of PEX3
and PEX16, but also bind to other regions of PEX3 and/or
PEX16 as it mediates the biogenesis of other PMPs. This is
not to say that an analysis of targeting signals and PEX19-
binding sites in PEX3 and PEX16 is unimportant. Rather,
it reflects our view that such studies will be extremely im-
portant not only for what they will tell us about general
PEX19–PMP interactions, but also for the information
they will provide on the roles of these three proteins in the
biogenesis of peroxisome membranes. In contrast, the
analysis of targeting elements and PEX19-binding sites in
PMPs that are not required for peroxisome membrane
synthesis, such as PMP70 and PEX11b, are likely to yield
data that relates only to the general role of PEX19 binding
in PMP biogenesis.
PEX19 Is Bimodally Distributed between Cytoplasm 
and Peroxisomes
To better understand how PEX19 facilitates peroxisome
membrane biogenesis, we assessed its distribution within
the cell. Subcellular fractionation, differential centrifuga-
tion, and differential permeabilization experiments all in-
dicated that there is a large population of cytosolic, soluble
PEX19, in addition to a peroxisomal pool of PEX19. Our
results are consistent with previously published data that
mammalian PEX19 is both cytoplasmic (James et al., 1994;
Matsuzono et al., 1999) and peroxisomal (James et al.,
1994; Kammerer et al., 1997; Matsuzono et al., 1999). A
similar bimodal distribution has been observed for yeast
forms of PEX19 (Gotte et al., 1998; Snyder et al., 1999).
Quantitation of the PEX19 levels in cytosolic and peroxi-
somal fractions of our rat liver gradient fractions suggest
that .95% of PEX19 may be cytoplasmic.
One potential caveat to our PEX19 distribution data is
related to PEX19 farnesylation. It is formally possible that
PEX19 utilizes its farnesyl moiety for association with per-
oxisomes and that our homogenization and permeabiliza-
tion procedures released PEX19 from peroxisomes with-
out disturbing peroxisome integrity in general. To assess
the general relevance of farnesylation to PEX19 function
we used site-directed mutagenesis to eliminate the farne-
sylation site. WT PEX19 and the resulting PEX19/C296A
mutant were assayed for their ability to restore peroxi-
some biogenesis in PEX19-deficient cells, and we found
that the mutant was almost fully active (80% of WT activ-
ity). High activity also has been reported for an analogous
CAAX box mutant of P. pastoris PEX19 (Snyder et al.,
1999). These studies strongly suggest that farnesylation
has an ancillary rather than a central role in PEX19 func-
tion, and makes it unlikely that PEX19 uses farnesylation
as its primary means for associating with peroxisomes. Our
results are based on the analysis of four independent, se-
quence-confirmed PEX19/C296A clones, and we have no
explanation for the previous report that a C296S mutant of
human PEX19 had no activity (Matsuzono et al., 1999).
Implications for PMP Import and
Peroxisome Biogenesis
In this report, we found that PEX19 binds to a diverse ar-
ray of PMPs, including metabolite transporters and perox-
ins, and that regions of PMPs which are sufficient for tar-
geting to peroxisomes retain the ability to interact with
PEX19. We also observed that PEX19 is a predominantly
cytoplasmic, partly peroxisomal protein, and that loss of
PEX19 results in the absence of detectable peroxisomalSacksteder et al. PEX19 Is a PMP-binding Protein 943
structures, the destabilization of many integral PMPs, and
the mislocalization of other PMPs to the mitochondrion.
One simple model that could explain these data is that
PEX19 plays an important role in the biogenesis of PMPs.
For instance, the bimodal distribution of PEX19 may rep-
resent a steady state view of a cycling PMP-binding
protein that facilitates the early steps in PMP biogene-
sis, either as a chaperone or as a PMP receptor. Such a
model provides many questions for future studies, such as
whether PEX19 is indeed a PMP receptor, whether
PEX19 binds PMPs in the cytoplasm before their import,
whether PEX19 cycles between cytoplasm and peroxi-
some, and whether PEX19 has additional roles when
present at the peroxisome membrane.
Existing data on peroxisome biogenesis in human cells
are consistent with the ability of cells to generate peroxi-
somes in two ways, either by growth and division of preex-
isting peroxisomes or by synthesis from an as yet unidenti-
fied preperoxisomal vesicle. In this model (South and
Gould, 1999), peroxisomes are defined as vesicles that
contain a normal or nearly normal complement of PMPs
(regardless of matrix protein content), whereas preperoxi-
somal vesicles are defined as vesicles that either lack
PMPs altogether or have only one or a small number of
PMPs. In our examination of PEX19-deficient cells, we
did not see PMPs present in any vesicles reminiscent of
peroxisomes or in any smaller vesicles. Instead, they were
either completely absent or mislocalized to the mitochon-
drion. Although we did not find any evidence for the early
remnants reported in pex19 mutants of P. pastoris by
Snyder et al. (1999), it is possible that we could have
missed such structures with the techniques that we em-
ployed.
Recent studies from yeast have suggested that the ER
may contribute to peroxisome synthesis (for reviews see
Kunau and Erdmann, 1998; Titorenko and Rachubinski,
1998), and the ER could, in fact, represent preperoxisomal
vesicles of our model. However, the hypothesis that the
ER plays a direct and essential role in peroxisome biogen-
esis still lacks evidence from multiple experimental sys-
tems that would be necessary for its general acceptance.
The results of this study do not directly address this ques-
tion, but it is worth noting that our results offer no clear
support for an ER role in peroxisome membrane synthe-
sis. For instance, we failed to observe accumulation of any
PMPs in the ER in the absence of PEX19, a result that
would be predicted for PMPs that transit through the ER
before their import into peroxisomes, as has been sug-
gested for PEX3 and PEX16 (for review see Kunau and
Erdmann, 1998; Titorenko and Rachubinski, 1998). Also,
the fact that PEX19 is a predominantly cytoplasmic PMP-
binding protein with an important role in PMP biogenesis
does lend some support to the model that PMPs, or at least
most PMPs, are synthesized on free polyribosomes and
imported directly from the cytoplasm into peroxisomes
(Lazarow and Fujiki, 1985).
We would like to thank Jim Morrell for excellent technical assistance,
Gail Stetten for aid with fluorescence microscopy, Tony Guerrerio (all
from The Johns Hopkins University School of Medicine, Baltimore, MD)
for analysis of binding data, and Skaidrite Krisans (San Diego State Uni-
versity, San Diego, CA) for the gift of purified rat liver peroxisomes.
This work was support by grants from the National Institutes of Health
and the March of Dimes to S.J. Gould (DK45787, HD10981, and MOD
FY93/94-0514). 
Submitted: 27 May 1999
Revised: 5 January 2000
Accepted: 21 January 2000
References
Adams, G.A., and J.K. Rose. 1985. Structural requirements of a membrane-
spanning domain for protein anchoring and cell surface transport. Cell. 41:
1007–1015.
Bjorkman, J., G. Stetten, C.S. Moore, S.J. Gould, and D.I. Crane. 1998. Ge-
nomic structure of PEX13, a candidate peroxisome biogenesis disorder
gene.  Genomics. 54:521–528.
Boursnell, M.E., T.D. Brown, and M.M. Binns. 1984. Sequence of the mem-
brane protein gene from avian coronavirus IBV. Virus Res. 1:303–313.
Braverman, N., G. Dodt, S.J. Gould, and D. Valle. 1995. Disorders of peroxi-
some biogenesis. Hum. Mol. Genet. 4:1791–1798.
Chang, C.-C., and S.J. Gould. 1998. Phenotype-genotype relationships in com-
plementation group 3 of the peroxisome-biogenesis disorders. Am. J. Hum.
Genet. 63:1294–1306.
Chang, C.-C., W.-H. Lee, H.W. Moser, D. Valle, and S.J. Gould. 1997. Isolation
of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis
disorders. Nat. Genet. 15:385–388.
Chang, C.-C., D.S. Warren, K.A. Sacksteder, and S.J. Gould. 1999a. PEX12
binds PEX5 and PEX10 and acts downstream of receptor docking in peroxi-
somal matrix protein import. J. Cell Biol. 147:761–764.
Chang, C.-C., S. South, D. Warren, J. Jones, A.B. Moser, H.W. Moser, and S.J.
Gould. 1999b. Metabolic control of peroxisome abundance. J. Cell Sci. 112:
1579–1590.
Dekker, P.J., P. Keil, J. Rassow, A.C. Maarse, N. Pfanner, and M. Meijer. 1993.
Identification of MIM23, a putative component of the protein import ma-
chinery of the mitochondrial inner membrane. FEBS (Fed. Eur. Biochem.
Soc.) Lett. 330:66–70.
Diestelkotter, P., and W.W. Just. 1993. In vitro insertion of the 22 kD peroxiso-
mal membrane protein into isolated rat liver peroxisomes. J. Cell Biol. 123:
1717–1725.
Dodt, G., and S.J. Gould. 1996. Multiple PEX genes are required for proper
subcellular distribution and stability of Pex5p, the PTS1 receptor: evidence
that PTS1 protein import is mediated by a cycling receptor. J. Cell Biol. 135:
1763–1774.
Dodt, G., N. Braverman, C. Wong, A. Moser, H.W. Moser, P. Watkins, D.
Valle, and S.J. Gould. 1995. Mutations in the PTS1 receptor gene, PXR1, de-
fine complementation group 2 of the peroxisome biogenesis disorders. Nat.
Genet. 9:115–124.
Drees, B.L. 1999. Progress and variations in two-hybrid and three-hybrid tech-
nologies. Curr. Opin. Chem. Biol. 3:64–70.
Dyer, J.M., J.A. McNew, and J.M. Goodman. 1996. The sorting sequence of the
peroxisomal integral membrane protein PMP47 is contained within a short
hydrophilic loop. J. Cell Biol. 133:269–280.
Evan, G.E., G.K. Lewis, G. Ramsay, and J.M. Bishop. 1985. Isolation of mono-
clonal antibodies specific for human c-myc proto-oncogene product. Mol.
Cell. Biol. 5:3610–3616.
Fransen, M., S.R. Terlecky, and S. Subramani. 1998. Identification of a human
PTS1 receptor docking protein directly required for peroxisomal protein im-
port. Proc. Natl. Acad. Sci. USA. 95:8087–8092.
Fujiki, Y., R.A. Rachubinski, and P.B. Lazarow. 1984. Synthesis of a major in-
tegral membrane polypeptide of rat liver peroxisomes on free polysomes.
Proc. Natl. Acad. Sci. USA. 81:7127–7131.
Geisbrecht, B.V., D. Zhang, H. Schulz, and S.J. Gould. 1999. Characterization
of PECI, a novel monofunctional delta3,delta2-enoyl-CoA isomerase of
mammalian peroxisomes. J. Biol. Chem. 274:21797–21803.
Gotte, K., W. Girzalsky, M. Linkert, E. Baumgart, S. Kammerer, W.-H. Kunau,
and R. Erdmann. 1998. Pex19p, a farnesylated protein essential for peroxi-
some biogenesis. Mol. Cell. Biol. 18:616–628.
Hettema, E.H., B. Distel, and H.F. Tabak. 1999. Import of proteins into peroxi-
somes. Biochim. Biophys. Acta. 1451:17–34.
Imanaka, T., G.M. Small, and P.B. Lazarow. 1987. Translocation of acyl-coA
oxidase into peroxisomes requires ATP hydrolysis but not a membrane po-
tential. J. Cell Biol. 105:2915–2922.
Imanaka, T., Y. Shiina, T. Hashimoto, and T. Osumi. 1996. Insertion of the 70-
kDa peroxisomal membrane protein into peroxisomal membranes in vivo
and in vitro. J. Biol. Chem. 271:3706–3713.
James, G.L., J.L. Goldstein, R.K. Pathak, R.G.W. Anderson, and M.S. Brown.
1994. PxF, a prenylated protein of peroxisomes. J. Biol. Chem. 269:14182–
14190.
Jones, J.M., K. Nau, M.T. Geraghty, R. Erdmann, and S.J. Gould. 1999. Identi-
fication of peroxisomal acyl-CoA thioesterases in yeast and humans. J. Biol.
Chem. 274:9216–9223.
Kamijo, K., S. Taketani, S. Yokata, T. Osumi, and T. Hashimoto. 1990. The 70
kDa peroxisomal membrane protein is a member of the Mdr (P-glycopro-
tein)-related ATP-binding protein superfamily. J. Biol. Chem. 265:4534–The Journal of Cell Biology, Volume 148, 2000 944
4540.
Kammerer, S., N. Arnold, W. Gutensohn, H.W. Mewes, W.H. Kunau, G. Hof-
ler, A.A. Roscher, and A. Braun. 1997. Genomic organization and molecu-
lar characterization of a gene encoding HsPXF, a human peroxisomal farne-
sylated protein. Genomics. 45:200–210.
Kammerer, S., A. Holzinger, U. Welsh, and A.A. Roscher. 1998. Cloning and
characterization of the gene encoding the human peroxisomal assembly pro-
tein Pex3p. FEBS (Fed. Eur. Biochem. Soc.) Lett. 429:53–60.
Kinoshita, N., K. Ghaedi, N. Shimozawa, R.J.A. Wanders, Y. Matsuzono, T.
Imanaka, K. Okumoto, Y. Suzuki, N. Kondo, and Y. Fujiki. 1998. Newly
identified Chinese hamster ovary cell mutants are defective in biogenesis of
peroxisomal membrane vesicles (peroxisomal ghosts), representing a novel
complementation group in mammals. J. Biol. Chem. 273:24122–24130.
Kunau, W.H., and R. Erdmann. 1998. Peroxisome biogenesis: back to the endo-
plasmic reticulum? Curr. Biol. 8:R299–R302.
Lawson, J.E., and M.G. Douglas. 1988. Separate genes encode functionally
equivalent ADP/ATP carrier proteins in Saccharomyces cerevisiae. Isolation
and analysis of AAC2. J. Biol Chem. 265:14812–14818.
Lazarow, P.B., and Y. Fujiki. 1985. Biogenesis of peroxisomes. Annu. Rev. Cell
Biol. 1:489–530.
Lazarow, P.B., and H.W. Moser. 1995. Disorders of peroxisome biogenesis. In
The Metabolic and Molecular Bases of Inherited Disease. C.R. Scriver, A.L.
Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill, New York. 2287–
2324.
Lombard-Platet, G., S. Savary, C.O. Sarde, J.L. Mandel, and G. Chimini. 1996.
A close relative of the adrenoileukodystrophy (ALD) gene codes for a per-
oxisomal protein with a specific expression pattern. Proc. Natl. Acad. Sci.
USA. 93:1265–1269.
Marzioch, M., R. Erdmann, M. Veenhuis, and W.-H. Kunau. 1994. PAS7 en-
codes a novel yeast member of the WD-40 protein family essential for im-
port of 3-oxoacyl-CoA thiolase, a PTS2-containing protein, into peroxi-
somes.  EMBO (Eur. Mol. Biol. Organ.) J. 13:4908–4918.
Matsuzono, Y., N. Kinoshita, S. Tamura, N. Shimozawa, M. Hamasaki, K.
Ghaedi, R.J. Wanders, Y. Suzuki, N. Kondo, and Y. Fujiki. 1999. Human
PEX19: cDNA cloning by functional complementation, mutation analysis in
a patient with Zellweger syndrome, and potential role in peroxisomal mem-
brane assembly. Proc. Natl. Acad. Sci. USA. 96:2116–2121.
McCollum, D., E. Monosov, and S. Subramani. 1993. The pas8 mutant of Pichia
pastoris exhibits the peroxisomal protein import deficiencies of Zellweger
syndrome cells. The PAS8 protein binds to the COOH-terminal tripeptide
peroxisomal targeting signal and is a member of the TPR protein family. J.
Cell Biol. 121:761–774.
Mihalik, S.J. 1992. Involvement of both peroxisomes and mitochondria in the
alpha-oxidation of phytanic acid. Prog. Clin. Biol. Res. 357:239–244.
Mosser, J., A.M. Douar, C.O. Sarde, P. Kioschis, R. Feil, H. Moser, A.M.
Poustka, J.L. Mandel, and P. Aubourg. 1993. Putative X-linked adrenoleu-
kodystrophy gene shares unexpected homology with ABC transporters. Na-
ture. 361:726–730.
Mosser, J., Y. Lutz, M.E. Stoeckel, C.O. Sarde, C. Kretz, A.M. Douar, J. Lopez,
P. Aubourg, and J.L. Mandel. 1994. The gene responsible for adrenoleuko-
dystrophy encodes a peroxisomal membrane protein. Hum. Mol. Genet.
3:265–271.
Murakami, H., G. Blobel, and D. Pain. 1990. Isolation and characterization of
the gene for a yeast mitochondrial import receptor. Nature. 347:488–491.
Reguenga, C., M.E. Oliveira, A.M. Gouveia, C. Eckerskorn, C. Sa-Miranda,
and J.E. Azevedo. 1999. Identification of a 24 kDa intrinsic membrane pro-
teins from mammalian peroxisomes. Biochim. Biophys. Acta. 1445:337–341.
Santos, M., T. Imanaka, H. Shio, G.M. Small, and P.B. Lazarow. 1988. Peroxi-
some membrane ghosts in Zellweger syndrome—aberrant organelle assem-
bly. Science. 239:1536–1538.
Schrader, M., B.E. Reuber, J.C. Morrell, G. Jimenez-Sanchez, C. Obie, T.
Stroh, D. Valle, T.A. Schroer, and S.J. Gould. 1998. Expression of PEX11b
mediates peroxisome proliferation in the absence of extracellular stimuli. J.
Biol. Chem. 273:29607–29614.
Snyder, W.B., K.N. Faber, T.J. Wenzel, A. Koller, G.H. Luers, L. Rangell, G.A.
Keller, and S. Subramani. 1999. PEX19 interacts with Pex3p and Pex10p and
is essential for peroxisome biogenesis in Pichia pastoris. Mol. Biol. Cell. 10:
1745–1761.
Soukupova, M., C. Sprenger, K. Gorgas, W.H. Kunau, and G. Dodt. 1999. Iden-
tification and characterization of the human peroxin PEX3. Eur. J. Cell Biol.
78:357–374.
South, S., and S.J. Gould. 1999. Peroxisome synthesis in the absence of preexist-
ing peroxisomes. J. Cell Biol. 144:255–266.
Subramani, S. 1993. Protein import into peroxisomes and biogenesis of the or-
ganelle. Annu. Rev. Cell Biol. 9:445–478.
Terlecky, S.R., W.M. Nuttley, D. McCollum, E. Sock, and S. Subramani. 1995.
The Pichia pastoris peroxisomal protein Pas8p is the receptor for the C-ter-
minal tripeptide peroxisomal targeting signal. EMBO (Eur. Mol. Biol. Or-
gan.) J. 14:3627–3634.
Titorenko, V.I., and R.A. Rachubinski. 1998. The endoplasmic reticulum plays
an essential role in peroxisome biogenesis. Trends Biochem. Sci. 23:231–233.
Vidal, M., R.K. Brachman, A. Fattaey, E. Harlow, and J.D. Boeke. 1996. Re-
verse two-hybrid and one-hybrid systems to detect dissociation of protein-
protein and DNA-protein interactions. Proc. Natl. Acad. Sci. USA. 93:
10315–10320.
Wanders, R.J., and J.M. Tager. 1998. Lipid metabolism in peroxisomes in rela-
tion to human disease. Mol. Aspects Med. 19:69–154.
Warren, D.S., J.C. Morrell, H.W. Moser, D. Valle, and S.J. Gould. 1998. Identi-
fication of PEX10, the gene defective in complementation group 7 of the
peroxisome-biogenesis disorders. Am. J. Hum. Genet. 63:347–359.
Wylin, T., M. Baes, C. Brees, G.P. Mannaerts, M. Fransen, and P.P. Van Veld-
hoven. 1999. Identification and characterization of human PMP34, a protein
closely related to the peroxisomal integral membrane protein PMP47 of
Candida boidinii. Eur. J. Biochem. 258:332–338.
Yahraus, T., N. Braverman, G. Dodt, J.E. Kalish, J.C. Morrell, H.W. Moser, D.
Valle, and S.J. Gould. 1996. The peroxisome biogenesis disorder group 4
gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the
PTS1 receptor. EMBO (Eur. Mol. Biol. Organ.) J. 15:2914–2923.